Introduction
Arsenic was used as a drug in the fifteenth century. It was orally administered for the treatment of syphilis and trichophytosis in the sixteenth century, typhinia in the seventeenth century, and cancer in the nineteenth century. Simple arsenic is considered non-toxic, but arsenic compounds , such as hydride (AsH3), oxides (As2O3, H3AsO3), sulfide (As2S3), and halide (AsF3), are toxic 0. Chinese and American researchers have reported that arsenic trioxide (ATO, As203) induced apoptosis not only in recurrent acute promyelocytic leukemia (APL) but also in other leukemic cells , and alleviated leukemia 2). Administration of ATO for the treatment of APL was officially approved in June 2000 by the Food and Drug Administration (FDA) in the USA3).
There have been a number of studies on the effects of ATO on patients with leukemia and leukemia-related cells, but only a few studies on the effects of ATO on solid tumors have been reported so far. Recently, basic studies using solid tumors, such as Signalerings Commissie Kanker (SCK) and frog skin angiotensin II (FSaII), are only recently begun 4) 5). We found suppressive effects of ATO on growth of solid tumor using SCC-VII, and also found synergistic suppressive effects of hyperthermia after ATO administration on tumor growth.
In this study, we examined the suppressive effects of different treatment sequences of ATO administration and hyperthermia on tumor growth in C3H/Hej mice with SCC-VII by measuring the tumor size. Changes in tumor cells were examined by microscopic observation of necrosis in excised sections treated by Hematoxylin and Eosinatain staining (HE staining).
Materials and methods

Experimental animals
Male C3H/Hej mice were purchased from Nihon LSC Inc. In each of the control , hyperthermia alone, ATO alone, A-H, and H-A groups, 50 mice were used for the measurement of the tumor volume, and 5 mice for pathological examination (total, 55 mice). The weight of all the mice was 21-26 g , and the age was 6 weeks. The mice were fed at a temperature of 22 + 0.2°C and a humidity of 60 + 5% in lighting from 6 : 00 a. m. to 6 : 00 p. m. in an animal-feeding building. The mice were freely allowed to take solid CE-2 (Nihon Clea Inc.) and filtered tap water.
Tumor SCC-VII tumor is a spontaneous cancer in C3H/Hej mice. SCC-VII cells stored at -80°C of a refrigerator were thawed and incubated in an incubator at a temperature of 37°C, a carbon dioxide concentration of 5%, and a sufficient humidity. 1 X 106 SCC-VII cells/0.05 ml per mouse were ( 
Results
Measurement of the tumor volume Figure 2 shows the tumor volume. The ordinate shows the tumor volume (mm3), and the abscissa the period (days) after the start of measurement. If the tumor volume in the treatment groups are smaller than that in the control group, the tumor growth was regarded as delayed.
As shown in Fig. 2 , the tumor growth was most delayed in the H-A group, and almost the same delay was observed in the A-H group. The hyperthermia alone and ATO alone groups showed similar delay of the tumor growth. The F test of the difference in the tumor growth during the observation period
between the A-H and H-A groups demonstrated that the variances were equal, and Student's t-test
demonstrated no difference in the tumor growth between the two groups. The period of tumor growth required for becoming four times bigger than the initial volume was 4.5 days in the control group, 6.0 days in the ATO alone group, 6.8 days in the hyperthermia alone group, 9.0 days in the H-A group, and 8.5 days in the A-H group. In other words, the delay of the tumor growth was 1.5 days in the ATO alone group, 2.3 days in the hyperthermia alone group, 4.5 days in the H-A group, and 4.0 days in the A-H group. When the delay of the tumor growth in the control group was regarded as 1, the ratio of the delay was 1.3 in the ATO alone group, 1.5 in the hyperthermia alone group, 2.0 in the H-A group, and 1.9 in the A-H group respectively. Based on these results, the co value was calculated to be 1.2 in the H-A group and 1.1 in the A-H group, indicating that the suppressive effects were synergistic in both groups. epidermal growth factor (EGF), and to change the membrane potential leading to the channel opening [13] [14] [15] [16] . Since the half-life of ATO in blood is reported to be about 12 hours 17), the suppression of tumor growth by ATO was most likely sustained at the time of hyperthermia performed 2 hours after ATO administration, suggesting that functional changes in the cell membrane by hyperthermia induced the synergistic suppressive effects of ATO on the tumor growth. This mechanism may cause the synergistic suppressive effects on the tumor growth in the A-H group. The duration of functional changes in the cell membrane by hyperthermia is unknown, but possibly the changes were sustained at the time of ATO administration performed 2 hours after the completion of hyperthermia, and the synergistic suppressive effects of ATO on the tumor growth may have been observed in the H-A group.
Therefore, this mechanism may induce the synergistic suppressive effects of ATO on the tumor growth not only in the A-H group but also in the H-A group.
Conclusion
As described above, the suppression of tumor growth by hyperthermia was enhanced by ATO administration, and the suppressive effects by ATO administration were enhanced by hyperthermia,
suggesting that there was no significant difference in the suppressive effects on the tumor growth between the treatment sequences of hyperthermia and ATO administration at an interval of 2 hours. In addition to the above mechanism, there may be a complex combination of other factors, such as suppression by ATO administration of the recovery from potentially lethal damage (PLD) caused by hyperthermia and suppression by hyperthermia of the recovery from PLD caused by ATO administration.
The results of this study did not indicate whether higher suppressive effects on the SCC-VII growth were obtained by hyperthermia followed by ATO administration or ATO administration followed by hyperthermia at an interval of 2 hours. of ATO and Hyperthermia •E T. Suzuki et al.
